Suma Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 1.45 Cr
as on 23-10-2024
- Company Age 33 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 58.58 Cr
as on 23-10-2024
- Satisfied Charges ₹ 26.16 Cr
as on 23-10-2024
- Revenue -31.83%
(FY 2023)
- Profit -25.71%
(FY 2023)
- Ebitda 36.03%
(FY 2023)
- Net Worth 15.21%
(FY 2023)
- Total Assets 55.44%
(FY 2023)
About Suma Pharmaceuticals
The Corporate was formerly known as Fast Real Honest Fabricators Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.45 Cr.
The company currently has active open charges totaling ₹58.58 Cr. The company has closed loans amounting to ₹26.16 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ganpat Patil and Sumati Patil serve as directors at the Company.
- CIN/LLPIN
U27100MH1991PTC062830
- Company No.
062830
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Aug 1991
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Suma Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ganpat Patil  | Director | 28-Dec-1997 | Current |
| Sumati Patil | Director | 28-Dec-1997 | Current |
Financial Performance of Suma Pharmaceuticals.
Suma Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 31.83% decrease. The company also saw a substantial fall in profitability, with a 25.71% decrease in profit. The company's net worth Soared by an impressive increase of 15.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Suma Pharmaceuticals?
In 2023, Suma Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aromatic And Industrial Chemicals Private LimitedActive 59 years 5 monthsGanpat Patil and Sumati Patil are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 24 May 2023 | ₹29.29 Cr | Open |
Bank Of India Creation Date: 15 Mar 2023 | ₹29.29 Cr | Open |
Others Creation Date: 29 Jun 2022 | ₹2.30 Cr | Satisfied |
How Many Employees Work at Suma Pharmaceuticals?
Suma Pharmaceuticals has a workforce of 15 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Suma Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Suma Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
